The once-a-day semaglutide pill is approved for reducing the risk of heart disease and Type 2 diabetes, the company said in a statement Monday.

The problem with the mass Ozempic advertising campaign is that it cultivates an impression that it's a 'wonder drug' that's going to help people lose weight, one doctor said.